RxDoctor Payments Data

Michael App, MD

Internal Medicine · Grand Rapids, MINPI 1467490953

Payments from drug & device makers

$12,705in general payments, 2019–2025

Across 818 payments — averaging $15.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$2K
  • AbbVie$1K
  • Pfizer$1K
  • Boehringer Ingelheim$641
  • Lilly USA, LLC$534
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$12,51498%
  • Education$1922%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca97$1,639
Novo Nordisk112$1,537
AbbVie(2 entities)134$1,395
Pfizer74$1,071
Boehringer Ingelheim38$641
Lilly USA, LLC35$534
Merck23$421
Teva Pharmaceuticals USA, Inc.22$416
Astellas Pharma US Inc13$350
GSK25$334
Amgen13$256
Otsuka America Pharmaceutical, Inc.13$252
Collegium Pharmaceutical, Inc.25$226
Exact Sciences10$221
Takeda Pharmaceuticals U.S.A., Inc.13$217
Bayer13$216
Supernus Pharmaceuticals, Inc.10$205
E.r. Squibb & Sons, L.L.C.12$193
Neos Therapeutics, LP12$174
Jazz Pharmaceuticals Inc.7$170
Ironshore Pharmaceuticals Inc.10$166
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC8$149
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)7$139
Novartis6$132
Sanofi-aventis U.S. LLC6$109
Daiichi Sankyo Inc.5$100
Xeris Pharmaceuticals, Inc.4$92
Kowa Pharmaceuticals America, Inc.6$90
Biohaven Pharmaceutical Holding Company Ltd.3$80
Sanofi Pasteur Inc.4$79
Cranial Technologies, Inc3$63
Johnson & Johnson4$62
Lundbeck LLC2$52
Axsome Therapeutics, Inc.2$50
Esperion Therapeutics, Inc.3$45
Inspire Medical Systems, Inc.2$45
Nestle Healthcare Nutrition Inc.3$44
Medtronic1$44
Myovant Sciences Inc.2$41
Inari Medical, Inc.2$37
Tris Pharma Inc2$36
Dexcom, Inc.2$35
Irhythm Technologies, Inc.1$32
Dermira, Inc.2$31
Idorsia Pharmaceuticals US Inc2$31
IBSA Pharma Inc.2$29
Genentech USA, Inc.2$28
Biohaven Pharmaceuticals, Inc.1$26
Zealand Pharma US, Inc.1$23
Noven Pharmaceuticals, Inc.1$23
Sage Therapeutics, LLC1$23
Eisai Inc.1$23
Actelion Pharmaceuticals US, Inc.1$22
Sumitomo Pharma America, Inc.1$21
ARS Pharmaceuticals Operations, Inc.1$20
Corcept Therapeutics1$20
Corium, LLC1$19
Globus Medical1$19
Paratek Pharmaceuticals, Inc.1$18
Regeneron Healthcare Solutions, Inc.1$17

How this compares

$12,705 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$77,637
Medicare patients
111
Services billed
17,101

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ArexvyRsvpref3 Antigen/As01e/Pf3,673$1,051,577
ShingrixVaricella-Zoster Ge/As01b/Pf2,921$598,210
AbrysvoRsv Vacc, Pref A And Pref B/Pf598$181,132
Boostrix TdapDiphth,pertuss(Acell),tet Vac1,543$99,539
EliquisApixaban90$73,105
MounjaroTirzepatide54$61,085
TwinrixHepatitis A And B Vaccine/Pf316$42,613
TrulicityDulaglutide35$36,343
OzempicSemaglutide29$32,083
MyrbetriqMirabegron30$28,918
FarxigaDapagliflozin Propanediol28$28,664
XareltoRivaroxaban30$26,834
HavrixHepatitis A Virus Vaccine/Pf181$17,451
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$9,549
Adacel TdapDiph,pertuss(Acell),tet Vac/Pf130$8,604

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKArexvy, Shingrix, Twinrix, Havrix, Trelegy Ellipta$334$1,719,4007,107 claims
PfizerAbrysvo, Eliquis$1,071$254,237688 claims
Lilly USA, LLCMounjaro, Trulicity$534$97,42889 claims
Novo NordiskOzempic$1,537$32,08329 claims
Astellas Pharma US IncMyrbetriq$350$28,91830 claims
AstraZenecaFarxiga$1,639$28,66428 claims
Johnson & JohnsonXarelto$62$26,83430 claims
MerckVaqta$421$2,59027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →